Retatrutide

Retatrutide adds glucagon-receptor agonism to the dual-incretin approach, aiming to increase energy expenditure alongside appetite suppression. Phase 2 results published in 2023 reported mean weight reductions approaching 24% at 48 weeks at the highest dose — the largest seen in an obesity trial at that time.

Phase 3 trials are ongoing. Retatrutide is not approved anywhere, yet it already circulates widely in gray-market channels — a pattern our testing program monitors closely, since unapproved late-stage compounds attract significant counterfeiting.